Tempus AI (TEM) announced the clinical launch of its Immune Profile Score (IPS) algorithmic test. IPS, which is now available for clinicians to order, is a multimodal biomarker that can be used as a ...

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its ...

IPS is a multimodal biomarker that combines known and novel clinical and immune-related biomarkers from DNA and RNA analysis to predict a patient's response to ICI-based therapy. The new clinical ...

AUSTIN, Texas--(BUSINESS WIRE)--July 12, 2006--TippingPoint, a division of 3Com, today announced that the TippingPoint(TM) 5000E Intrusion Prevention System (IPS) was one of only three products to ...